

Effect of Aspirin on Cardiovascular Events and Bleeding

New England Journal of Medicine

379, 1509-1518

DOI: [10.1056/nejmoa1805819](https://doi.org/10.1056/nejmoa1805819)

Citation Report

#	ARTICLE	IF	CITATIONS
4	More Evidence to Help Guide Decision Making About Aspirin for Primary Prevention. <i>Annals of Internal Medicine</i> , 2018, 169, 804.	3.9	3
5	Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3621.	4.1	17
6	Primary vascular prevention: The end of the road for aspirin?. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 475-476.	2.0	0
7	In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years. <i>Annals of Internal Medicine</i> , 2018, 169, JC67.	3.9	2
8	Adverse effects of aspirin in healthy elderly. <i>Reactions Weekly</i> , 2018, 1721, 5-5.	0.0	0
9	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1857-1865.	1.8	16
10	Should Aspirin Be Used for Primary Prevention in the Post-Statins Era?. <i>New England Journal of Medicine</i> , 2018, 379, 1572-1574.	27.0	75
11	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1499-1508.	27.0	392
12	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1519-1528.	27.0	591
13	Daily aspirin doesn't prevent deaths or disability in healthy older people, trial finds. <i>BMJ: British Medical Journal</i> , 2018, , k3923.	2.3	0
15	Response by Mehra and Colombo to Letter Regarding Article, "Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the Heartmate 3 Versus the Heartmate II Cardiac Pump". <i>Circulation</i> , 2019, 140, e165-e166.	1.6	1
16	Aspirin for the primary prevention of cardiovascular disease: latest evidence. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 633-643.	1.5	20
17	A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. <i>American Journal of Medicine</i> , 2019, 132, 1295-1304.e3.	1.5	16
18	Aspirin and Primary Prevention in Patients with Diabetes: A Critical Evaluation of Available Randomized Trials and Meta-Analyses. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1573-1582.	3.4	6
19	The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies. <i>Ophthalmology</i> , 2019, 126, 1647-1656.	5.2	13
21	Real world evidence in cardiovascular medicine: ensuring data validity in electronic health record-based studies. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 1189-1194.	4.4	53
22	Polypharmacy and Rational Prescribing: Changing the Culture of Medicine One Patient at a Time. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2019, 7, 141-158.	0.8	4
23	Population-based case-control study: chemoprotection of colorectal cancer with non-aspirin nonsteroidal anti-inflammatory drugs and other drugs for pain control. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 295-305.	3.7	9

#	ARTICLE	IF	CITATIONS
24	An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 561-573.	1.5	2
25	Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-32.	4.0	369
26	Variability in aspirin efficacy: all in the genes?. <i>European Heart Journal</i> , 2019, 40, 3393-3396.	2.2	3
27	<i>Bifidobacterium breve</i> Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers. <i>Gastroenterology</i> , 2019, 157, 637-646.e4.	1.3	50
28	Metal-Organic Framework-Derived Carbon Nanostructures for Site-Specific Dual-Modality Photothermal/Photodynamic Thrombus Therapy. <i>Advanced Science</i> , 2019, 6, 1901378.	11.2	78
29	Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 283-291.	2.2	8
30	Estándares SEA 2019 para el control global del riesgo cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 1-43.	0.8	8
32	HEART UK consensus statement on Lipoprotein(a): A call to action. <i>Atherosclerosis</i> , 2019, 291, 62-70.	0.8	142
33	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	2.8	39
34	Ischaemic stroke. <i>Nature Reviews Disease Primers</i> , 2019, 5, 70.	30.5	849
35	Cohort Profile: The ASPREE Longitudinal Study of Older Persons (ALSOP). <i>International Journal of Epidemiology</i> , 2019, 48, 1048-1049h.	1.9	36
36	Gut Microbiota-Mediated Drug-Drug Interaction between Amoxicillin and Aspirin. <i>Scientific Reports</i> , 2019, 9, 16194.	3.3	25
37	Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. <i>BMC Medicine</i> , 2019, 17, 198.	5.5	71
38	The appropriateness of antiplatelet and anticoagulant drug prescriptions in hospitalized patients in an internal medicine ward. <i>Aging Clinical and Experimental Research</i> , 2019, 33, 2849-2855.	2.9	2
39	Aspirin for Primary Prevention of Cardiovascular Disease. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 162.	3.5	2
40	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019, 70, 1-7.	2.2	17
41	Don't stop the statin!. <i>European Heart Journal</i> , 2019, 40, 3526-3528.	2.2	2
42	Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes. <i>Stroke</i> , 2019, 50, 3057-3063.	2.0	23

#	ARTICLE	IF	CITATIONS
43	Aspirin in primary prevention: the triumph of clinical judgement over complex equations. Internal and Emergency Medicine, 2019, 14, 1217-1231.	2.0	4
44	Effects of Colorectal Cancer Risk Factors on the Association Between Aspirin and Colorectal Cancer. Anticancer Research, 2019, 39, 4877-4884.	1.1	4
45	Platelet antioxidants: A conundrum in aging. EBioMedicine, 2019, 47, 29-30.	6.1	1
46	The effect of low-dose aspirin on colorectal cancer prevention and gastrointestinal bleeding according to bodyweight and body mass index: Analysis of UK primary care data. International Journal of Cardiology, 2019, 297, 135-139.	1.7	4
47	Platelets Are at the Nexus of Vascular Diseases. Frontiers in Cardiovascular Medicine, 2019, 6, 132.	2.4	48
48	<p>The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1129-1140.	2.0	9
49	Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiology, 2019, 4, 1131.	6.1	47
50	The role of aspirin as antiaggregant therapy in primary prevention. An update. Medicina Cl�nica (English Edition), 2019, 153, 326-331.	0.2	1
51	Costs of bleeding on long-term antiplatelet treatment without routine co-prescription of proton-pump inhibitors. International Journal of Stroke, 2021, 16, 719-726.	5.9	6
52	Benefits of Magnetic Resonance Imaging for Patients Presenting With Low-risk Transient or Persistent Minor Neurologic Deficits. JAMA Neurology, 2019, 76, 1421.	9.0	3
53	Rate and Prognosis of Brain Ischemia in Patients With Lower-Risk Transient or Persistent Minor Neurologic Events. JAMA Neurology, 2019, 76, 1439.	9.0	60
54	Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation, 2019, 140, 1115-1124.	1.6	33
55	Aspirin for Primary Prevention. JAMA - Journal of the American Medical Association, 2019, 321, 253.	7.4	12
56	Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events. JAMA - Journal of the American Medical Association, 2019, 321, 277.	7.4	399
57	Understanding and preventing atherosclerosis: from bench to bedside. European Heart Journal, 2019, 40, 323-327.	2.2	4
58	Prevalence of chronic kidney disease in the elderly using the ASPirin in Reducing Events in the Elderly study cohort. Nephrology, 2019, 24, 1248-1256.	1.6	12
59	Aspirin for primary cardiovascular disease prevention: time to re�evaluate guidelines?. Internal Medicine Journal, 2019, 49, 133-134.	0.8	1
60	Aspirin for primary cardiovascular disease prevention: what we know and what we don�t know. Internal Medicine Journal, 2019, 49, 12-14.	0.8	1

#	ARTICLE	IF	CITATIONS
62	American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 674-694.	2.6	2,318
63	Recent Evidence Examining Efficacy and Safety of Aspirin for Primary Cardiovascular Disease Prevention. <i>Annals of Pharmacotherapy</i> , 2019, 53, 738-745.	1.9	0
64	The Combination of Curcumin and Salsalate is Superior to Either Agent Alone in Suppressing Pro-Cancerous Molecular Pathways and Colorectal Tumorigenesis in Obese Mice. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1801097.	3.3	17
66	Genetic variation at the coronary artery disease risk locus <i>GUCY1A3</i> modifies cardiovascular disease prevention effects of aspirin. <i>European Heart Journal</i> , 2019, 40, 3385-3392.	2.2	25
67	Role of aspirin in primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 675-686.	13.7	97
68	What Is So Hard About Aspirin for Primary Prevention?. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2930-2931.	2.8	3
69	Aspirin for Primary Prevention of Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2915-2929.	2.8	89
70	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. <i>AIDS Research and Therapy</i> , 2019, 16, 11.	1.7	13
71	Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. <i>EBioMedicine</i> , 2019, 44, 28-40.	6.1	37
72	Biology of frailty: Implications for clinical pharmacology and drug therapy in frail older people. <i>Mechanisms of Ageing and Development</i> , 2019, 181, 22-28.	4.6	28
74	Polypills for primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 602-611.	13.7	26
75	Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2019, 18, 70.	6.8	46
76	Should aspirin be used for primary prevention in the healthy elderly?. <i>Evidence-based Nursing</i> , 2019, 22, 115-115.	0.2	0
77	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-7.	1.1	5
78	Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence. <i>Advances in Preventive Medicine</i> , 2019, 2019, 1-14.	2.7	5
79	The Parachute Paradox: What Works in Public Health and Continual Improvement in the Asia Pacific <i>Journal of Public Health</i> . <i>Asia-Pacific Journal of Public Health</i> , 2019, 31, 381-383.	1.0	0
80	The rise and fall of aspirin in the primary prevention of cardiovascular disease. <i>Lancet</i> , The, 2019, 393, 2155-2167.	13.7	140
81	Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond: Medical and Ethical Issues. <i>Current Treatment Options in Neurology</i> , 2019, 21, 27.	1.8	0

#	ARTICLE	IF	CITATIONS
82	Low-Dose Aspirin for the Primary Prevention of Cardiovascular Disease in Diabetic Individuals: A Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 609.	2.4	12
83	Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin. <i>JAMA Oncology</i> , 2019, 5, 911.	7.1	1
84	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. <i>CNS Drugs</i> , 2019, 33, 685-694.	5.9	8
85	“Doctor, Should I Keep Taking an Aspirin a Day?” <i>New England Journal of Medicine</i> , 2019, 380, 1967-1970.	27.0	17
86	Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease. <i>JAMA Neurology</i> , 2019, 76, 906.	9.0	53
87	Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit? A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 478-489.	2.7	22
88	Cerebral Venous Thrombosis. <i>Stroke</i> , 2019, 50, 1598-1604.	2.0	32
89	Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1387-1403.	2.5	32
90	Effects of Aspirin in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2019, 380, 1775-1777.	27.0	1
91	Aspirin for primary prevention: Is this the end of the road?. <i>Indian Heart Journal</i> , 2019, 71, 113-117.	0.5	8
92	Prevalence of depressive symptoms and its associated factors among healthy community-dwelling older adults living in Australia and the United States. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1208-1216.	2.7	56
93	Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. <i>Annals of Medicine</i> , 2019, 51, 182-192.	3.8	12
94	Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. <i>Cardiovascular Research</i> , 2019, 115, 1178-1188.	3.8	79
95	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 140, e596-e646.	1.6	1,789
96	Involvement of the anti-inflammatory, anti-apoptotic, and anti-secretory activity of bee venom in its therapeutic effects on acetylsalicylic acid-induced gastric ulceration in rats. <i>Toxicology</i> , 2019, 419, 11-23.	4.2	26
97	Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3 inflammasome activation in LPS-induced vascular injury. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 711-723.	12.0	64
98	Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett’s Esophagus?. <i>Gastroenterology</i> , 2019, 156, 1228-1231.	1.3	3
99	Engaging GP’s and primary care patients in research: implications of the ASPREE trial for future studies. <i>Medical Journal of Australia</i> , 2019, 210, 159-160.	1.7	0

#	ARTICLE	IF	CITATIONS
100	Aspirin for the Primary Prevention of Cardiovascular Disease: Weighing Up the Evidence. American Journal of Medicine, 2019, 132, 1007-1008.	1.5	4
101	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. Journal of the American College of Cardiology, 2019, 74, 1376-1414.	2.8	820
102	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 74, e177-e232.	2.8	1,038
103	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e563-e595.	1.6	1,676
104	Aspirin and nonsteroidal anti-inflammatory drug use and keratinocyte cancers: a large population-based cohort study of skin cancer in Australia. British Journal of Dermatology, 2019, 181, 749-760.	1.5	21
106	Evidence-Based Cardiovascular Risk Management in Diabetes. American Journal of Cardiovascular Drugs, 2019, 19, 439-448.	2.2	10
107	Aspirin for the primary prevention of cardiovascular disease in the elderly. BMJ Evidence-Based Medicine, 2019, 24, 143-144.	3.5	3
108	Novel Antiplatelet Therapies for Atherothrombotic Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 546-557.	2.4	47
109	Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study. Diabetes, Obesity and Metabolism, 2019, 21, 1409-1418.	4.4	15
110	Is Alzheimer's Disease Risk Modifiable?. Journal of Alzheimer's Disease, 2019, 67, 795-819.	2.6	73
111	Noise, pollution, food, or medication: what really matters in primary prevention?. European Heart Journal, 2019, 40, 563-566.	2.2	0
112	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. International Journal of Cardiology, 2019, 286, 198-207.	1.7	23
113	Results of the ASCEND study: time to abandon aspirin for the primary prevention of cardiovascular disease in people with diabetes. Practical Diabetes, 2019, 36, 4.	0.3	1
114	Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention. Annals of Internal Medicine, 2019, 171, 529.	3.9	16
115	Cases in Precision Medicine: A Personalized Approach to Stroke and Cardiovascular Risk Assessment in Women. Annals of Internal Medicine, 2019, 171, 837.	3.9	2
116	Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease. Annals of Internal Medicine, 2019, 170, 357.	3.9	23
117	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2019. Diabetes Care, 2019, 42, S103-S123.	8.6	676
119	Increased risk of aspirin-induced gastric mucosal erosion in elderly Chinese men harboring SLCO1B1*1b/*1b while using aspirin and an ACEI or ARB concomitantly. BMC Medical Genetics, 2019, 20, 183.	2.1	3

#	ARTICLE	IF	CITATIONS
120	2019 AGS Beers Criteria for older adults. <i>Pharmacy Today</i> , 2019, 25, 42-54.	0.0	21
122	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S105-S113.	1.2	9
123	Clinical trials in long-term antiplatelet therapies. <i>Current Opinion in Cardiology</i> , 2019, 34, 315-322.	1.8	2
124	Stroke in the elderly. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019, 167, 393-418.	1.8	27
125	Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. <i>PLoS ONE</i> , 2019, 14, e0224580.	2.5	3
126	Medication Use Quality and Safety in Older Adults: 2018 Update. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2458-2462.	2.6	4
127	Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. <i>Journal of Hypertension</i> , 2019, 37, 1301-1307.	0.5	8
128	Diabetes and Cardiovascular Disease: an Update. <i>Current Diabetes Reports</i> , 2019, 19, 161.	4.2	53
129	Aspirin for primary prevention in elderly hypertensive patients. <i>Journal of Hypertension</i> , 2019, 37, 1154-1156.	0.5	1
130	Aspirin for primary prevention of cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2019, 34, 510-513.	1.8	1
131	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 299-311.	2.2	13
132	The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!. <i>European Heart Journal</i> , 2019, 40, 618-620.	2.2	10
133	Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019, 40, 607-617.	2.2	124
134	Screening for Cardiovascular Disease. Too Early and Too Late?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 57, 451.	1.5	0
135	A farewell to aspirin in primary prevention?. <i>Nature Reviews Cardiology</i> , 2019, 16, 76-77.	13.7	3
136	Regaining pre-fracture basic mobility status after hip fracture and association with post-discharge mortality and readmission—a nationwide register study in Denmark. <i>Age and Ageing</i> , 2019, 48, 278-284.	1.6	36
137	Aspirin for primary prevention of cardiovascular disease in diabetes. <i>Journal of Diabetes Investigation</i> , 2019, 10, 899-901.	2.4	4
138	Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 157-163.	2.7	14

#	ARTICLE	IF	CITATIONS
139	The first 3500 years of aspirin history from its roots – A concise summary. <i>Vascular Pharmacology</i> , 2019, 113, 1-8.	2.1	132
140	Aspirin and Cancer Prevention in the Elderly: Where Do We Go From Here?. <i>Gastroenterology</i> , 2019, 156, 534-538.	1.3	23
141	Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 746-749.	1.8	6
142	Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2034-2041.	1.8	13
143	Increased risk of stroke and myocardial infarction in patients with epilepsy: A systematic review of population-based cohort studies. <i>Epilepsy and Behavior</i> , 2020, 104, 106307.	1.7	34
144	Aspirin for primary prevention of stroke in individuals without cardiovascular disease – A meta-analysis. <i>International Journal of Stroke</i> , 2020, 15, 9-17.	5.9	18
145	Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease. <i>Heart Failure Reviews</i> , 2020, 25, 381-391.	3.9	22
146	Editorial commentary: MicroRNAs as effectors and indicators of aspirin therapeutic potential. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 255-256.	4.9	0
147	Modulators of platelet function in aging. <i>Platelets</i> , 2020, 31, 474-482.	2.3	14
148	Does low-dose aspirin initiated before 11 weeks gestation reduce the rate of preeclampsia?. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 437-450.	1.3	40
149	Chemoprevention of Colorectal Cancer. <i>Gastroenterology</i> , 2020, 158, 368-388.	1.3	126
150	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 57-68.	3.0	13
151	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
152	Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 327-333.	1.3	4
153	Preventive Management of Nonobstructive CAD After Coronary CT Angiography in the Emergency Department. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 437-448.	5.3	20
154	Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 37-46.	2.0	9
155	Modulation of microRNAs by aspirin in cardiovascular disease. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 249-254.	4.9	26
156	Aspirin in primary prevention of cardiovascular disease in the elderly. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 326-327.	3.0	2

#	ARTICLE	IF	CITATIONS
157	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 108008.	2.8	18
158	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk—A Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 199-206.	3.4	5
159	Changing place for aspirin in primary prevention of cardiovascular disease. <i>Drug and Therapeutics Bulletin</i> , 2020, 58, 3-4.	0.3	1
162	Aspirin for the Primary Prevention of Cardiovascular Disease. <i>Cardiology in Review</i> , 2020, 28, 98-106.	1.4	4
163	Biomarkers in primary prevention. <i>Herz</i> , 2020, 45, 10-16.	1.1	6
164	A comparison of contemporary versus older studies of aspirin for primary prevention. <i>Family Practice</i> , 2020, 37, 290-296.	1.9	10
165	Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2020, 14, 213-221.	1.8	12
166	Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. <i>Drugs and Aging</i> , 2020, 37, 43-55.	2.7	8
167	Effect of aspirin on semen quality: A review. <i>Andrologia</i> , 2020, 52, e13487.	2.1	9
168	Review of the top 5 cardiology studies of 2017-18. <i>Canadian Pharmacists Journal</i> , 2020, 153, 32-36.	0.8	2
169	The role of aspirin in the prevention of ovarian, endometrial and cervical cancers. <i>Women's Health</i> , 2020, 16, 174550652096171.	1.5	6
170	Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. <i>Current Atherosclerosis Reports</i> , 2020, 22, 75.	4.8	27
171	Reply to "Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?" by Evesque et al.. <i>Annals of Oncology</i> , 2020, 31, 1261-1262.	1.2	0
172	Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature. <i>JRSM Cardiovascular Disease</i> , 2020, 9, 204800402094932.	0.7	17
173	Aspirin for primary prevention of ST segment elevation myocardial infarction in persons with diabetes and multiple risk factors. <i>EclinicalMedicine</i> , 2020, 27, 100548.	7.1	6
174	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	2.2	93
175	Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future. <i>Current Rheumatology Reports</i> , 2020, 22, 84.	4.7	19
176	Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Tj ETQq1 1 0.784314 rgBT /Over	1.6	7

#	ARTICLE	IF	CITATIONS
177	Aspirin to prevent gastrointestinal cancer “ but recent trial data do not fit. <i>Annals of Oncology</i> , 2020, 31, 1262-1263.	1.2	1
178	Influence of Sex on Platelet Reactivity in Response to Aspirin. <i>Journal of the American Heart Association</i> , 2020, 9, e014726.	3.7	21
179	Baseline characteristics and age-related macular degeneration in participants of the “ASpirin in Reducing Events in the Elderly” (ASPREE)-AMD trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 20, 100667.	1.1	10
180	Baseline characteristics predicting clinical outcomes and serious adverse events in middle-aged hypertensive women: a subanalysis of the SPRINT in women aged <65 years. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1298-1306.	0.9	0
181	Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. <i>Circulation</i> , 2020, 142, 2172-2188.	1.6	26
182	Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000453.	2.7	5
183	Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0237022.	2.5	15
184	Contemporary trends in antiplatelet prescription in Australia. <i>Journal of Pharmacy Practice and Research</i> , 2020, 50, 366-368.	0.8	0
185	Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	10
186	Novel Approaches to Fine-Tune Therapeutic Targeting of Platelets in Atherosclerosis: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1492-1504.	3.4	6
187	Antihypertensive medication use and blood pressure control among treated older adults. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1406-1414.	2.0	4
188	Aspirin decreases human sperm motility and vitality, chelates seminal calcium, but insignificantly reduces seminal nitric oxide production. <i>Andrologia</i> , 2020, 52, e13776.	2.1	8
189	<i>CYP2C19</i> genotype-guided antiplatelet therapy: promises and pitfalls. <i>Pharmacogenomics</i> , 2020, 21, 889-897.	1.3	13
190	Response. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 461.	1.0	1
191	Aspirin: Bitter pill or miracle drug?. <i>Clinical Biochemistry</i> , 2020, 85, 1-4.	1.9	11
192	Increased dipeptidyl peptidase-4 accelerates chronic stress-related thrombosis in a mouse carotid artery model. <i>Journal of Hypertension</i> , 2020, 38, 1504-1513.	0.5	18
193	Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population. <i>Stroke and Vascular Neurology</i> , 2020, 5, 270-278.	3.3	17
194	10. Cardiovascular Disease and Risk Management: “Standards of Medical Care in Diabetes”2020. <i>Diabetes Care</i> , 2020, 43, S111-S134.	8.6	421

#	ARTICLE	IF	CITATIONS
195	Direct-to-consumer genetic testing for factor V Leiden and prothrombin 20210G>A: the consumer experience. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1468.	1.2	4
196	All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study. <i>BMJ Open</i> , 2020, 10, e030034.	1.9	6
197	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. <i>Circulation</i> , 2020, 142, 1579-1590.	1.6	28
198	Atypical Spontaneous Hematomas in a Patient with Severe Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 856-858.	2.7	16
199	Prevention of preeclampsia with aspirin. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S1108-S1119.	1.3	140
200	The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases. <i>Rheumatology</i> , 2020, 59, 3593-3602.	1.9	2
201	Purification and Characterization of Novel Collagen Peptides against Platelet Aggregation and Thrombosis from <i>Salmo salar</i> . <i>ACS Omega</i> , 2020, 5, 19995-20003.	3.5	11
202	<p>Increased Risk of Clopidogrel-Induced Gastric Mucosal Erosion in Elderly Chinese Men Harboring the ABC1 3435T Allele</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 1237-1244.	2.5	1
203	Should Aspirin Be Prescribed to Prevent Recurrence in Nonarteritic Anterior Ischemic Optic Neuropathy?. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 428-433.	0.8	3
204	Cardiometabolic disease in the older person: prediction and prevention for the generalist physician. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 90-95.	1.1	19
205	Prevention of Intracerebral and Subarachnoid Haemorrhage. , 2020, , 463-484.		0
206	Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9585.	4.1	32
207	Risk-Benefit Events Associated with the Use of Aspirin for Primary Prevention of Cardiovascular Disorders. , 2020, , .		0
208	Impact of the 2017 American Heart Association and American College of Cardiology hypertension guideline in aged individuals. <i>Journal of Hypertension</i> , 2020, 38, 2527-2536.	0.5	3
209	Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly. <i>Hypertension</i> , 2020, 76, 1945-1952.	2.7	21
210	Assessment of Physician Priorities in Delivery of Preventive Care. <i>JAMA Network Open</i> , 2020, 3, e2011677.	5.9	13
211	The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2144-2154.	2.4	14
212	High-dose PPI and aspirin as chemoprevention in Barrett's oesophagus. <i>Drug and Therapeutics Bulletin</i> , 2020, 58, 39-40.	0.3	0

#	ARTICLE	IF	CITATIONS
213	Primary prevention of myocardial infarction: aspirin is not as useful as it seems. <i>Annals of Translational Medicine</i> , 2020, 8, 361-361.	1.7	1
214	A Systematic Review of the Efficacy and Safety of Aspirin When Delivered at Different Medication Times for the Primary and Secondary Prevention of Cardiovascular and Cerebrovascular Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1339-1348.	1.6	2
215	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020, 36, 596-624.	1.7	324
216	2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease. <i>Chinese Medical Journal</i> , 2020, 133, 1221-1223.	2.3	7
217	Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2602-2618.	2.8	175
218	Nutrition, Thrombosis, and Cardiovascular Disease. <i>Circulation Research</i> , 2020, 126, 1415-1442.	4.5	35
219	Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists. <i>Canadian Pharmacists Journal</i> , 2020, 153, 153-160.	0.8	1
220	Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic. <i>Life Sciences</i> , 2020, 253, 117720.	4.3	4
221	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 88.	2.4	82
222	Effect of Aspirin vs Placebo on the Prevention of Depression in Older People. <i>JAMA Psychiatry</i> , 2020, 77, 1012.	11.0	47
223	Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 456-465.	2.0	14
224	Twilight, the Dawn of a New Era of Aspirin-Free PCI?. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2425-2429.	2.8	6
225	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	4.1	17
226	Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. <i>Current Cardiology Reports</i> , 2020, 22, 48.	2.9	5
227	The quest to slow ageing through drug discovery. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 513-532.	46.4	260
228	Familial Hypercholesterolemia in a Healthy Elderly Population. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002938.	3.6	8
229	Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 17-27.	2.8	27
230	Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1289-1298.	4.7	13

#	ARTICLE	IF	CITATIONS
231	cGMP Signaling in Cardiovascular Diseases. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 516-525.	1.9	15
232	Aspirin Should Not Be Recommended to Prevent Second Eye Involvement in Patients With Nonarteritic Anterior Ischemic Optic Neuropathy. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 271-273.	0.8	2
233	Who needs acetylsalicylic acid? Some order after many studies. <i>European Heart Journal Supplements</i> , 2020, 22, E37-E39.	0.1	1
235	Structural modification of aspirin to design a new potential cyclooxygenase (COX-2) inhibitors. In <i>Silico Pharmacology</i> , 2020, 8, 1.	3.3	25
236	Risk Assessment in Oral Health. , 2020, , .		2
237	No Modulation of the Effect of Aspirin by Body Weight in Healthy Older Men and Women. <i>Circulation</i> , 2020, 141, 1110-1112.	1.6	5
238	After ASPREE: Assessing Aspirin Usage in Older Adults Using an Interprofessional Approach. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1107-1108.	2.6	1
239	Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2020, 9, e013560.	3.7	6
240	Aspirin for primary prevention of cardiovascular disease in women. <i>Menopause</i> , 2020, 27, 605-606.	2.0	2
241	Primary Prevention Statins in Older Patients. <i>Journal of the American College of Cardiology</i> , 2020, 76, 28-30.	2.8	3
242	The World Goes Bats: Living Longer and Tolerating Viruses. <i>Cell Metabolism</i> , 2020, 32, 31-43.	16.2	89
243	Aspirin for Lynch syndrome: a legacy of prevention. <i>Lancet, The</i> , 2020, 395, 1817-1818.	13.7	4
244	Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4541.	2.6	1
245	Rates and Predictors of Patient Underreporting of Hospitalizations During Follow-Up After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006231.	2.2	6
246	Platelets as therapeutic targets to prevent atherosclerosis. <i>Atherosclerosis</i> , 2020, 307, 97-108.	0.8	47
247	Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience. <i>International Journal of Cardiology</i> , 2020, 320, 78-82.	1.7	5
248	Cardiovascular Events after Community-Acquired Pneumonia: A Global Perspective with Systematic Review and Meta-Analysis of Observational Studies. <i>Journal of Clinical Medicine</i> , 2020, 9, 414.	2.4	37
249	The Prevention of Cardiovascular Disease in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1098-1106.	2.6	15

#	ARTICLE	IF	CITATIONS
250	Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study. <i>BMC Geriatrics</i> , 2020, 20, 22.	2.7	19
251	Caspase-11 promotes allergic airway inflammation. <i>Nature Communications</i> , 2020, 11, 1055.	12.8	52
252	Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study. <i>BioMed Research International</i> , 2020, 2020, 1-8.	1.9	9
253	Aspirin Use and Awareness for Cardiovascular Disease Prevention Among Hispanics: Prevalence and Associations with Health Behavior Beliefs. <i>Journal of Community Health</i> , 2020, 45, 820-827.	3.8	3
254	A review of drugs that contribute to bleeding risk in general dental practice. <i>Australian Dental Journal</i> , 2020, 65, 118-130.	1.5	4
255	Incidence and Predictors of Aspirin Discontinuation in Older Adult Veteran Nursing Home Residents at End of Life. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 725-735.	2.6	10
256	Urgent to correctly understand the role of aspirin in cardiovascular disease. <i>International Journal of Cardiology</i> , 2020, 310, 33.	1.7	0
257	ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. <i>Pharmaceuticals</i> , 2020, 13, 7.	3.8	8
258	Adoption of coronary artery disease - Reporting and Data System (CAD-RADS [®] , [®]) and observed impact on medical therapy and systolic blood pressure control. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 421-427.	1.3	9
259	Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality. <i>Journal of the American Heart Association</i> , 2020, 9, e014668.	3.7	24
260	Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 2974-2982.	2.2	185
261	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , 2020, 18, 125-138.	1.7	9
262	Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. <i>Journal of Critical Care</i> , 2020, 58, 34-40.	2.2	0
263	Prevalence and disease predisposition of p.A91V perforin in an aged population of European ancestry. <i>Blood</i> , 2020, 135, 582-584.	1.4	6
264	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.	2.1	3
265	Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2021, 6, 179.	6.1	55
266	The ASPREE Trial: An Unanticipated Stimulus for Greater Precision in Prevention?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 221-222.	6.3	5
267	Intracerebral haemorrhage, microbleeds and antithrombotic drugs. <i>Revue Neurologique</i> , 2021, 177, 11-22.	1.5	3

#	ARTICLE	IF	CITATIONS
268	Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 118-119.	1.0	7
269	Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 95.e1-95.e12.	1.3	71
270	Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 186-195.	10.7	32
271	Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. <i>American Journal of Cardiology</i> , 2021, 141, 38-48.	1.6	12
272	Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature. <i>Thrombosis and Haemostasis</i> , 2021, 121, 553-564.	3.4	18
273	Hypertension Canada's 2020 hypertension guidelines for pharmacists: An update. <i>Canadian Pharmacists Journal</i> , 2021, 154, 19-25.	0.8	4
274	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2021. <i>Diabetes Care</i> , 2021, 44, S125-S150.	8.6	359
275	Repurposing drugs to fight aging: The difficult path from bench to bedside. <i>Medicinal Research Reviews</i> , 2021, 41, 1676-1700.	10.5	16
276	Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases. <i>American Journal of Preventive Medicine</i> , 2021, 60, 513-519.	3.0	7
277	Clinical decision-making: Challenging traditional assumptions. <i>International Journal of Cardiology</i> , 2021, 326, 6-11.	1.7	3
278	The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 139-151.	2.2	6
279	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. <i>Kidney International</i> , 2021, 99, 466-474.	5.2	18
280	Aspirin use predicts prolonged survival in patients with oropharyngeal cancer: Nationwide Veterans Affairs database study. <i>Head and Neck</i> , 2021, 43, 247-254.	2.0	1
281	Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 83-91.	1.8	7
282	Association Between Long-Term Aspirin Use and Frailty in Men: The Physicians' Health Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1077-1083.	3.6	7
283	Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade: why it could be a novel paradigm?. , 2021, , 167-191.		0
284	Anticoagulation and Antiplatelet Guidelines. , 2021, , 201-223.		0
285	Prevention of Cardiovascular Disease. , 2021, , 33-54.		0

#	ARTICLE	IF	CITATIONS
287	Schlaganfall "Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. The Springer Reference Pflege, Gesundheit, 2021, , 751-762.	0.3	0
288	Shared Decision Making. , 2021, , 169-192.		0
289	Long-Term Aspirin Use and Self-Reported Walking Speed in Older Men: The Physicians' Health Study. Journal of Frailty & Aging, 2022, 11, 1-6.	1.3	1
290	The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?. Familial Cancer, 2021, 20, 9-11.	1.9	0
291	A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?. European Heart Journal, 2021, 42, 561-562.	2.2	2
292	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. European Heart Journal, 2022, 43, 940-958.	2.2	8
293	Aspirin in the Modern Era of Cardiovascular Disease Prevention. Methodist DeBakey Cardiovascular Journal, 2021, 17, 36-47.	1.0	10
294	Aspirin in people with dementia, long-term benefits, and harms: a systematic review. European Journal of Clinical Pharmacology, 2021, 77, 943-954.	1.9	13
295	Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial. Molecular Psychiatry, 2021, 26, 5161-5170.	7.9	18
297	Age-Dependent Differences in the Rate and Symptoms of TIA Mimics in Patients Presenting With a Suspected TIA to a Neurological Emergency Room. Frontiers in Neurology, 2021, 12, 644223.	2.4	2
298	Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018. Journal of the American Geriatrics Society, 2021, 69, 1272-1282.	2.6	19
299	"To take or not to take an aspirin?"-The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease. Kidney International, 2021, 99, 308-310.	5.2	2
300	Complex chronic patients as an emergent group with high risk of intracerebral haemorrhage: an observational cohort study. BMC Geriatrics, 2021, 21, 106.	2.7	2
301	Pretreatment with antiplatelet drugs improves the cardiac function after myocardial infarction without reperfusion in a mouse model. Cardiology Journal, 2021, 28, 118-128.	1.2	6
302	Carotid stenosis management: time to address the misconceptions (furphies™). Nature Reviews Cardiology, 2021, 18, 383-384.	13.7	4
303	5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. British Journal of Cancer, 2021, 124, 1959-1969.	6.4	7
304	A Cohort Study of Anticholinergic Medication Burden and Incident Dementia and Stroke in Older Adults. Journal of General Internal Medicine, 2021, 36, 1629-1637.	2.6	12
305	Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. Clínica E Investigación En Arteriosclerosis (English Edition), 2021, 33, 85-107.	0.2	4

#	ARTICLE	IF	CITATIONS
306	Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105581.	1.6	7
307	Common Medications and Intracerebral Hemorrhage: The ARIC Study. <i>Journal of the American Heart Association</i> , 2021, 10, e014270.	3.7	8
308	Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial. <i>BMJ Open</i> , 2021, 11, e044695.	1.9	1
309	Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100149.	3.0	87
310	Cancer in older adults – Insights from the ASPREE trial. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1259-1260.	1.0	0
313	Comentario del CEIPV a la actualizaci3n de las Gu3as Europeas de Prevenci3n Vascul ar en la Pr3ctica Cl3nica. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 85-107.	0.8	1
314	Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials. <i>Journal of Hypertension</i> , 2021, 39, 1689-1696.	0.5	1
315	Antithrombotic Management of Elderly Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 723-738.	2.9	22
316	An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 605-618.	2.6	4
317	Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1379-1385.	6.3	14
318	Overview of Aspirin and Platelet Biology. <i>American Journal of Cardiology</i> , 2021, 144, S2-S9.	1.6	22
319	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 445.	9.0	33
320	Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence. <i>American Journal of Cardiology</i> , 2021, 144, S15-S22.	1.6	16
321	Enhancing Value and Uptake for Whole-Population Cohorts of Children and Parents: Methods to Integrate Registries into the Generation Victoria Cohort. <i>Children</i> , 2021, 8, 285.	1.5	1
322	Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2847.	1.4	3
323	Involving elderly research participants in the co-design of a future multi-generational cohort study. <i>Research Involvement and Engagement</i> , 2021, 7, 23.	2.9	5
324	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 441-452.	2.0	1
325	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	27.0	145

#	ARTICLE	IF	CITATIONS
326	Aspirin and antiplatelet treatments in cancer. <i>Blood</i> , 2021, 137, 3201-3211.	1.4	49
327	Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition. <i>Journal of Clinical Medicine</i> , 2021, 10, 2317.	2.4	5
328	Importance of circadian timing for aging and longevity. <i>Nature Communications</i> , 2021, 12, 2862.	12.8	106
329	Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty. <i>Current Cardiology Reports</i> , 2021, 23, 67.	2.9	6
330	Effect of APOE and a polygenic risk score on incident dementia and cognitive decline in a healthy older population. <i>Aging Cell</i> , 2021, 20, e13384.	6.7	16
332	ESO Guideline on covert cerebral small vessel disease. <i>European Stroke Journal</i> , 2021, 6, CXI-CLXII.	5.5	68
333	Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2021, 87, 3-12.	2.2	10
334	Surface Wettability of Nanoparticle Modulated Sonothrombolysis. <i>Advanced Materials</i> , 2021, 33, e2007073.	21.0	28
335	My Treatment Approach to Giant Cell Arteritis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1530-1545.	3.0	12
336	Association of life satisfaction with disability-free survival: role of chronic diseases and healthy lifestyle. <i>Age and Ageing</i> , 2021, 50, 1657-1665.	1.6	5
337	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. <i>Pharmacological Reviews</i> , 2021, 73, 924-967.	16.0	359
338	Review of the top 5 geriatrics studies of 2018-2019. <i>Canadian Pharmacists Journal</i> , 2021, 154, 256-261.	0.8	2
339	Aspirin and omega-3 fatty acid status interact in the prevention of cardiovascular diseases in Framingham Heart Study. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 169, 102283.	2.2	3
340	A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1387-1394.	1.5	1
341	Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 800-814.	2.7	12
342	Use of Preventive Aspirin Among Older US Adults With and Without Diabetes. <i>JAMA Network Open</i> , 2021, 4, e2112210.	5.9	16
343	Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network. <i>Primary Care Diabetes</i> , 2021, 15, 1075-1079.	1.8	2
345	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018. <i>Scientific Reports</i> , 2021, 11, 13603.	3.3	8

#	ARTICLE	IF	CITATIONS
346	Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. <i>Lancet, The</i> , 2021, 397, 2487-2496.	13.7	162
347	Design and Methodology of a Multicenter Randomized Clinical Trial to Evaluate the Efficacy of Tongmai Jiangtang Capsules in Type 2 Diabetic Coronary Heart Disease Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 625785.	3.5	2
348	Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. <i>Npj Genomic Medicine</i> , 2021, 6, 51.	3.8	11
349	Daily Low-Dose Aspirin, Diabetes, and Age—Still Looking for a Balance. <i>JAMA Network Open</i> , 2021, 4, e2112875.	5.9	0
350	Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3145-3156.	2.8	38
351	A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 154, 3-31.	2.3	34
352	Genomic Risk Prediction for Breast Cancer in Older Women. <i>Cancers</i> , 2021, 13, 3533.	3.7	6
353	Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention. <i>Pharmacotherapy</i> , 2021, , .	2.6	3
354	Negatively charged nanoparticles of multiple materials inhibit shear-induced platelet accumulation. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 35, 102405.	3.3	2
355	Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis. <i>Atherothrombosis</i> , 2021, , 89-105.	0.3	1
356	Sex hormones, vascular factors and cognition. <i>Frontiers in Neuroendocrinology</i> , 2021, 62, 100927.	5.2	11
357	Dispositional Optimism and All-Cause Mortality in Older Adults: A Cohort Study. <i>Psychosomatic Medicine</i> , 2021, 83, 938-945.	2.0	1
358	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. <i>Open Heart</i> , 2021, 8, e001710.	2.3	1
359	Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients. <i>Scientific Reports</i> , 2021, 11, 15258.	3.3	2
360	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
361	Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 297-301.	1.9	2
362	The pharmacotherapeutic management of duodenal and gastric ulcers. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 63-89.	1.8	3
363	Differences in the prevention and control of cardiovascular and cerebrovascular diseases. <i>Pharmacological Research</i> , 2021, 170, 105737.	7.1	26

#	ARTICLE	IF	CITATIONS
364	Deprescribing in Hospice Patients: Discontinuing Aspirin, Multivitamins, and Statins. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 721-726.	2.4	3
365	Aspirin Use and Risk of Subdural Hematoma: Updated Meta-Analysis of Randomized Trials. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105911.	1.6	2
366	Leukoaraiosis and acute ischemic stroke. European Journal of Neuroscience, 2021, 54, 6202-6213.	2.6	5
367	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	1.8	220
368	Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. Annals of Neurology, 2021, 90, 763-776.	5.3	9
369	Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. Journal of the American Heart Association, 2021, 10, e020330.	3.7	4
370	Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population. Stroke, 2021, 52, 2882-2891.	2.0	15
371	Health-related quality of life and incident cardiovascular disease events in community-dwelling older people: A prospective cohort study. International Journal of Cardiology, 2021, 339, 170-178.	1.7	17
372	Vascular origin in acute transient visual disturbance: A prospective study. European Journal of Neurology, 2021, 28, 4098-4108.	3.3	0
373	Effects of aspirin and statin use on venous thromboembolism prophylaxis and survival in patients with endometrial cancer. Expert Opinion on Drug Safety, 2022, 21, 335-347.	2.4	0
374	Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2814-2824.	3.8	27
376	The Relationship Between Caffeine and Caffeinated Drinks in Causing Intracranial Hemorrhage in the Elderly Aspirin-Taking Population: A Systematic Review. Cureus, 2021, 13, e17783.	0.5	2
377	Estimating heterogeneous survival treatment effects of lung cancer screening approaches: A causal machine learning analysis. Annals of Epidemiology, 2021, 62, 36-42.	1.9	9
378	Aspirin: Friend or enemy?. IJC Heart and Vasculature, 2021, 36, 100874.	1.1	0
379	Ageing and Women's Health. Clinics in Geriatric Medicine, 2021, 37, 533-541.	2.6	0
380	Explanatory survival model for nursing home residents- a 9-year retrospective cohort study. Archives of Gerontology and Geriatrics, 2021, 97, 104497.	3.0	7
381	Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use. American Journal of Preventive Cardiology, 2021, 8, 100256.	3.0	22
382	Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR. European Journal of Medicinal Chemistry, 2021, 225, 113804.	5.5	28

#	ARTICLE	IF	CITATIONS
383	Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110337.	3.2	5
385	The role of aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1949-1952.	1.8	1
386	An Update on Aspirin for Cardioprevention: Implications for Patient Care. , 2021, 70, S1-S10.		0
388	Aspirin in primary prevention of cardiovascular disease in diabetes. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2021, 6, 109-114.	1.0	1
389	Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 592116.	3.5	9
390	Aspirin in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome: An Old, Low-Cost Therapy With a Strong Rationale. <i>Anesthesia and Analgesia</i> , 2021, 132, 927-929.	2.2	1
391	Aspirin in the Prevention of Cardiovascular Disease and Cancer. <i>Annual Review of Medicine</i> , 2021, 72, 473-495.	12.2	17
392	Specialized Pro-resolving Mediators Directs Cardiac Healing and Repair with Activation of Inflammation and Resolution Program in Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1161, 45-64.	1.6	16
393	Stem and Progenitor Cells in the Pathogenesis and Treatment of Digestive Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1201, 125-157.	1.6	3
394	Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis. <i>American Journal of Medicine</i> , 2020, 133, 1056-1064.	1.5	10
395	Clinical approach to the inflammatory etiology of cardiovascular diseases. <i>Pharmacological Research</i> , 2020, 159, 104916.	7.1	56
398	Effect of Aspirin on Activities of Daily Living Disability in Community-Dwelling Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2007-2014.	3.6	13
399	Perioperative management of antiplatelet therapy in noncardiac surgery. <i>Current Opinion in Anaesthesiology</i> , 2020, 33, 454-462.	2.0	15
400	Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. <i>Journal of Clinical Investigation</i> , 2019, 129, 1845-1862.	8.2	136
401	Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019. <i>Anesthesia and Analgesia</i> , 2021, 132, 930-941.	2.2	253
402	What Do the Guidelines Really Say About Aspirin?. <i>Texas Heart Institute Journal</i> , 2018, 45, 228-230.	0.3	3
403	Aspirin for primary cardiovascular prevention: advice for a decisional strategy still based on risk stratification. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 70-78.	0.9	11
404	Aspirin for primary prevention in the elderly. <i>Aging</i> , 2019, 11, 6618-6619.	3.1	8

#	ARTICLE	IF	CITATIONS
405	Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2019, 1, 30.	0.1	2
406	Effects of aspirin on the gastrointestinal tract: Pros vs. cons (Review). <i>Oncology Letters</i> , 2020, 20, 2567-2578.	1.8	18
407	Aspirin for primary prevention of atherosclerotic cardiovascular events. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 300-311.	1.3	8
408	Caspase-4: A Therapeutic Target for Peptic Ulcer Disease. <i>ImmunoHorizons</i> , 2020, 4, 627-633.	1.8	6
409	Quo vadis, aspirin?. <i>EuroIntervention</i> , 2018, 14, e1153-e1157.	3.2	2
410	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 787-891.	0.8	102
411	Alcohol consumption and risks of cardiovascular disease and all-cause mortality in healthy older adults. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e230-e232.	1.8	4
412	Would You Recommend Aspirin to This Patient for Primary Prevention of Atherosclerotic Cardiovascular Disease?. <i>Annals of Internal Medicine</i> , 2021, 174, 1439-1446.	3.9	3
413	Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress. <i>Current Atherosclerosis Reports</i> , 2021, 23, 76.	4.8	4
414	Synthesis of a polyacetylene derivative bearing aspirin with chiral charge carrier "chiralions". <i>Journal of Macromolecular Science - Pure and Applied Chemistry</i> , 2022, 59, 53-58.	2.2	3
415	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	5.1	28
416	Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 467-476.	1.9	5
417	US taskforce advises against low dose aspirin for primary prevention of cardiovascular disease. <i>BMJ</i> , The, 2021, 375, n2521.	6.0	6
418	The role of platelets in the pathogenesis of atherosclerosis. , 2021, 17, 106-119.	0.1	0
419	Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies. <i>Thrombosis and Haemostasis</i> , 2022, 122, 445-455.	3.4	14
420	Management of stroke in patients on antithrombotic therapy: Practical issues in the era of direct oral anticoagulants. <i>Revue Neurologique</i> , 2021, , .	1.5	0
422	Cardiovascular Risk Calculators and their Applicability to South Asians. <i>Current Diabetes Reviews</i> , 2021, 17, e100120186497.	1.3	2
423	A daily aspirin might not be what the doctor ordered. <i>Nature</i> , 2018, 561, 437-437.	27.8	0

#	ARTICLE	IF	CITATIONS
424	The role of aspirin in primary prevention of cardiovascular diseases. <i>Cardiologia Croatica</i> , 2018, 13, 419-419.	0.0	0
426	Actual aspects in the primary prevention of cardiovascular diseases. <i>Medic Ro</i> , 2019, 5, 32.	0.0	0
429	Patient with diabetes after acute coronary event. How to improve forecast?. <i>Medical Alphabet</i> , 2019, 1, 6-11.	0.2	0
430	Aspirin for primary prevention of cardiovascular events: what are the evidences?. <i>Universa Medicina</i> , 2019, 38, 145-146.	0.2	0
432	Papel de la Aspirina® como tratamiento antiagregante en prevención primaria. <i>Puesta al día. Medicina Clínica</i> , 2019, 153, 326-331.	0.6	1
434	Long-Term Aspirin Use and 5-Year Survival in Healthy Adults: A Population-Based Cohort Study in South Korea. <i>Yonsei Medical Journal</i> , 2020, 61, 997.	2.2	0
437	Uso do Ácido acetilsalicílico na prevenção primária: novas evidências. <i>Revista Da Faculdade De Ciências Médicas De Sorocaba</i> , 2020, 21, 191-192.	0.2	0
438	CPC: A Case of Cardiac Arrest in a 94-year-old Woman during Treatments of Heart Failure and Pneumonia after Hematemesis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 1992-2011.	0.0	0
439	Bleeding complications in <i>bcr</i>-<i>abl</i>-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients. <i>European Journal of Haematology</i> , 2022, 108, 154-162.	2.2	6
440	Risk Assessment in CVD. , 2020, , 33-60.		0
441	Prevention of Heart Failure. <i>Contemporary Cardiology</i> , 2021, , 489-512.	0.1	1
442	Prevention of Ischemic Stroke. <i>Contemporary Cardiology</i> , 2021, , 581-609.	0.1	0
443	Aspirin for Primary Preventionâ€”Unveiling a Historical Truth and Choosing the Right Patient. <i>Indian Journal of Clinical Cardiology</i> , 2020, 1, 129-131.	0.1	0
444	Antiplatelet Therapy. <i>Contemporary Cardiology</i> , 2021, , 249-288.	0.1	0
445	Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. <i>Journal of Clinical Hypertension</i> , 2021, 23, 352-362.	2.0	3
446	Primary Prevention of Cardiovascular Disease Guidelines. <i>Contemporary Cardiology</i> , 2021, , 653-672.	0.1	0
447	The Discovery of Druggable Anti-aging Agents. <i>Annals of Geriatric Medicine and Research</i> , 2020, 24, 232-242.	1.8	6
450	Primary prevention aspirin among the elderly: challenges in translating trial evidence to the clinic. <i>British Journal of Cardiology</i> , 2020, , .	0.2	1

#	ARTICLE	IF	CITATIONS
451	Health Maintenance and Preventive Care in Older Adults with Dementia. , 2020, , 219-233.		0
452	Peptic and Marginal Ulcer Disease. , 2020, , 191-194.		0
453	Nutritional Role of Fatty Acids. , 2020, , 135-149.		1
454	Cardiovascular Disease in Women Part 2: Prevention, Identification, and Treatment of Cardiovascular Disease. , 2020, , 361-374.		0
455	Causal Inference and Assessment of Risk in the Health Sciences. , 2020, , 7-22.		0
456	Platelets in the Pathogenesis of Vascular Disease and Their Role as a Therapeutic Target. , 2020, , 233-261.		0
457	Current and Emerging Therapies for Atherosclerosis. , 2020, , 71-88.		0
458	Cardiovascular drug labeling: Do they have information on necessary precautions for older people?. Geriatrics Gerontology and Aging, 2020, 14, 196-202.	0.3	2
459	For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	0
461	Les méta-analyses en recherche clinique: forces et faiblesses. Medecine Des Maladies Metaboliques, 2020, 14, 239-249.	0.1	0
462	A Randomized Double-blind Placebo-controlled Trial of Oral Aspirin for Protection of Melanocytic Nevi Against UV-induced DNA Damage. Cancer Prevention Research, 2022, 15, 129-138.	1.5	1
463	Should my older adult patients take aspirin for primary prevention of cardiovascular disease?. Cleveland Clinic Journal of Medicine, 2021, 88, 632-634.	1.3	0
464	Aspirin prescribing pattern and guidelines-adherence evaluation for primary prevention of cardiovascular diseases at a teaching hospital. Saudi Pharmaceutical Journal, 2021, 29, 1426-1431.	2.7	0
465	A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. Endocrine Practice, 2020, 26, 787-793.	2.1	6
468	Kontroverze - aspirin po PCI? Aspirin po PCI: pro a protiv. Intervencni A Akutni Kardiologie, 2020, 19, 184-186.	0.0	0
469	Primary Prevention of Coronary Artery Disease. , 2021, , 81-123.		0
470	Hypertension and Hypercholesterolemia: is it Time for Anti-Lipid Therapy?. Rational Pharmacotherapy in Cardiology, 2020, 16, 842-851.	0.8	0
471	Aspirin for Primary Cardiovascular Prevention. Are we making a mistake for decades?. Mjedicinska, 2018, 13, 176-178.	0.1	0

#	ARTICLE	IF	CITATIONS
472	Top studies relevant to primary care from 2018: From PEER. Canadian Family Physician, 2019, 65, 260-263.	0.4	0
474	Update on acetylsalicylic acid for primary prevention of cardiovascular disease: Not initiating is not the same thing as discontinuing. Canadian Family Physician, 2019, 65, 481-482.	0.4	3
475	Acetylsalicylic acid for primary prevention of cardiovascular events. Canadian Family Physician, 2019, 65, 480.	0.4	0
476	For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?. Canadian Journal of Hospital Pharmacy, 2020, 73, 58-61.	0.1	0
477	PURL: Aspirin, Yes, for at-risk elderly-but what about the healthy elderly?. Journal of Family Practice, 2020, 69, E16-E18.	0.2	0
478	Considerations for optimal prescribing in older adults. Canadian Family Physician, 2020, 66, 584-587.	0.4	0
480	Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery, 2021, 1, 70-104.	0.5	13
481	Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy. Digestive Diseases and Sciences, 2022, 67, 4161-4169.	2.3	1
482	Role of AMPK mediated pathways in autophagy and aging. Biochimie, 2022, 195, 100-113.	2.6	68
483	Aspirin and statin therapy for primary prevention of cardiovascular disease in older adults. Heart, 2022, 108, 1090-1097.	2.9	8
484	A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. Cancers, 2021, 13, 5815.	3.7	7
485	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. ESC Heart Failure, 2022, 9, 685-694.	3.1	10
486	Cardiovascular risk prediction in healthy older people. GeroScience, 2022, 44, 403-413.	4.6	11
487	Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk. International Journal of Molecular Sciences, 2021, 22, 12380.	4.1	5
488	Guideline No. 422e: Menopause and Cardiovascular Disease. Journal of Obstetrics and Gynaecology Canada, 2021, 43, 1438-1443.e1.	0.7	9
489	The Effect of Low-Dose Aspirin on Frailty Phenotype and Frailty Index in Community-Dwelling Older Adults in the ASPirin in Reducing Events in the Elderly Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2007-2014.	3.6	9
490	Directive clinique no 422e: MÃ©nopause et maladies cardiovasculaires. Journal of Obstetrics and Gynaecology Canada, 2021, 43, 1444-1449.e1.	0.7	0
491	The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population. Thrombosis and Haemostasis, 2022, 122, 1130-1138.	3.4	1

#	ARTICLE	IF	CITATIONS
493	AcetylsalicylsÄure: Heutiger Stellenwert in der antithrombotischen Therapie. , 0, , .		0
494	Hypertensive disorders during pregnancy and risk of cardiovascular disease. Profilklicheskaya Meditsina, 2021, 24, 97.	0.6	1
495	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€”From Population to Patient-Centered Approaches. Frontiers in Cardiovascular Medicine, 2022, 9, 805525.	2.4	12
497	Clinical Management of Thrombotic Antiphospholipid Syndrome. Journal of Clinical Medicine, 2022, 11, 735.	2.4	11
498	Discontinuing low-dose acetylsalicylic acid after gastrointestinal bleeding is associated with increased mortality. Scandinavian Journal of Gastroenterology, 2022, , 1-7.	1.5	1
499	Colorectal Cancer Survivorsâ€™ Receptivity toward Genomic Testing and Targeted Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Cancer Recurrence. Journal of Community Genetics, 2022, 13, 201-214.	1.2	2
500	Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCUITCOMES121007979.	2.2	7
501	Antiplatelet therapy in cardiovascular disease: Current status and future directions. British Journal of Clinical Pharmacology, 2022, 88, 2686-2699.	2.4	21
502	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology, 2022, 76, 492-501.	7.3	26
503	EstÃndares SEA 2022 para el control global del riesgo cardiovascular. ClÃnica E InvestigaciÃn En Arteriosclerosis, 2022, 34, 130-179.	0.8	11
504	Cardiovascular disease in the elderly: proceedings of the European Society of Cardiologyâ€™ Cardiovascular Round Table. European Journal of Preventive Cardiology, 2022, 29, 1412-1424.	1.8	13
505	Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. American Heart Journal, 2022, 248, 72-83.	2.7	15
506	Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. The Lancet Healthy Longevity, 2022, 3, e109-e118.	4.6	15
507	Transitions from health to disease in older populations. The Lancet Healthy Longevity, 2022, 3, e79-e80.	4.6	1
508	A multistate model of health transitions in older people: a secondary analysis of ASPREE clinical trial data. The Lancet Healthy Longevity, 2022, 3, e89-e97.	4.6	10
509	Impact of statin use on major adverse cardiovascular events in patients with normal stress myocardial perfusion imaging and elevated coronary artery calcium score. Singapore Medical Journal, 2022, , .	0.6	0
510	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€™2022</i>. Diabetes Care, 2022, 45, S144-S174.	8.6	282
511	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences, 2021, 22, 13079.	4.1	20

#	ARTICLE	IF	CITATIONS
512	Proper Use and Reversal of Antithrombotic Drugs. Japanese Journal of Neurosurgery, 2022, 31, 159-164.	0.0	0
513	Trajectories of physical health-related quality of life and the risk of incident cardiovascular disease events and all-cause mortality in older people. American Heart Journal Plus, 2022, 13, 100117.	0.6	1
514	Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review. Semergen, 2022, , .	0.5	0
515	Update on Management of Cardiovascular Diseases in Women. Journal of Clinical Medicine, 2022, 11, 1176.	2.4	20
516	Assessment of the hepatorenal and hematological parameters of rats exposed to graded doses of lysine acetylsalicylate. Journal of Taibah University for Science, 2022, 16, 214-223.	2.5	1
518	Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis. Internal Medicine Journal, 2022, 52, 318-321.	0.8	2
519	Does Stopping Aspirin Differ Fundamentally From Not Starting Aspirin in the Primary Prevention of Cardiovascular Disease Among Older Adults?. Annals of Internal Medicine, 2022, , .	3.9	3
520	Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial. Annals of Internal Medicine, 2022, 175, 761-764.	3.9	8
521	Healthy Behaviors, Leisure Activities, and Social Network Prolong Disability-Free Survival in Older Adults With Diabetes. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2093-2101.	3.6	2
522	Non-Arteritic Anterior Ischemic Optic Neuropathy: Challenges for the Future. Frontiers in Ophthalmology, 2022, 2, .	0.5	0
523	American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. American Journal of Gastroenterology, 2022, 117, 542-558.	0.4	38
524	American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Journal of the Canadian Association of Gastroenterology, 2022, 5, 100-101.	0.3	6
525	Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals. Cancer Prevention Research, 2022, 15, 447-454.	1.5	5
526	Fruitflow inhibits platelet function by suppressing Akt/GSK3 β , Syk/PLC β 2 and p38 MAPK phosphorylation in collagen-stimulated platelets. BMC Complementary Medicine and Therapies, 2022, 22, 75.	2.7	2
527	Statins and Colorectal Cancer Risk: A Population-Based Case-Control Study and Synthesis of the Epidemiological Evidence. Journal of Clinical Medicine, 2022, 11, 1528.	2.4	4
528	Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19. JAMA Network Open, 2022, 5, e223890.	5.9	31
529	Ten things to know about ten cardiovascular disease risk factors “ 2022. American Journal of Preventive Cardiology, 2022, 10, 100342.	3.0	34
530	Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference?. Russian Journal of Cardiology, 2021, 26, 4734.	1.4	1

#	ARTICLE	IF	CITATIONS
531	Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 1097-1117.	1.5	4
532	Primary and Secondary Prevention of CAD: A Review. <i>International Journal of Angiology</i> , 2022, 31, 016-026.	0.6	2
533	Adjusted Morbidity Groups and Intracerebral Haemorrhage: A Retrospective Primary Care Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13320.	2.6	0
534	Frontiers of cardiovascular polyphills: From atherosclerosis and beyond. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 182-189.	4.9	3
535	The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study. <i>Drugs and Aging</i> , 2022, 39, 97-106.	2.7	1
536	Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortality. <i>BMC Geriatrics</i> , 2021, 21, 711.	2.7	43
537	A polygenic risk score predicts mosaic loss of chromosome Y in circulating blood cells. <i>Cell and Bioscience</i> , 2021, 11, 205.	4.8	5
538	The Association of Dispositional Optimism and Pessimism With Cardiovascular Disease Events in Older Adults: A Prospective Cohort Study. <i>Journal of Aging and Health</i> , 2022, , 089826432210831.	1.7	2
539	Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2022, 80, 810-813.	1.9	2
540	Prediction of disability-free survival in healthy older people. <i>GeroScience</i> , 2022, 44, 1641-1655.	4.6	7
541	Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. <i>Trials</i> , 2022, 23, 331.	1.6	8
542	Prior oral protonâ€pump inhibitor use is associated with reduced severity of aspirinâ€related upper gastrointestinal bleeding in older people. <i>Internal Medicine Journal</i> , 2022, 52, 663-666.	0.8	3
543	GuÃa ESC 2021 sobre la prevenciÃ³n de la enfermedad cardiovascular en la prÃ¡ctica clÃnica. <i>Revista Espanola De Cardiologia</i> , 2022, 75, 429.e1-429.e104.	1.2	27
544	Analysis of Aspirin Use and Cardiovascular Events and Mortality Among Adults With Hypertension and Controlled Systolic Blood Pressure. <i>JAMA Network Open</i> , 2022, 5, e226952.	5.9	2
546	Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1435-1442.	3.4	3
547	Should Patients Take Aspirin for Primary Cardiovascular Prevention?. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1552.	7.4	2
548	Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1585.	7.4	71
549	Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1598.	7.4	16

#	ARTICLE	IF	CITATIONS
550	Aspirin Use to Prevent Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2022, 327, 1577.	7.4	151
551	Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. Journal of Intensive Care Medicine, 2022, 37, 1238-1249.	2.8	3
553	OUP accepted manuscript. Cardiovascular Research, 2022, , .	3.8	1
554	Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention. International Journal of Molecular Sciences, 2022, 23, 4840.	4.1	6
555	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. Frontiers in Pharmacology, 2022, 13, 878416.	3.5	2
556	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3235.	1.4	37
557	A Collagenâ€Derived Oligopeptide from <i>Salmo salar</i> Collagen Hydrolysates Restrains Atherogenesis in ApoE ^{â€“} Mice via Targeting P ₂ Y ₁₂ Receptor. Molecular Nutrition and Food Research, 2022, , 2200166.	3.3	2
558	Association of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease. JAMA Network Open, 2022, 5, e2211107.	5.9	1
559	Do drugs interact together in cardiovascular prevention? A meta-analysis of powerful or factorial randomized controlled trials. Therapie, 2022, , .	1.0	1
560	Management of blunt cerebrovascular injuries at a Canadian level 1 trauma centre: Are we meeting the grade?. Canadian Journal of Surgery, 2022, 65, E303-E309.	1.2	3
561	Various bioactive peptides in collagen hydrolysate from salmo salar skin and the combined inhibitory effects on atherosclerosis in vitro and in vivo. Food Research International, 2022, 157, 111281.	6.2	9
562	Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry. Radiology: Cardiothoracic Imaging, 2022, 4, e210225.	2.5	6
563	Four recommendations for aspirin use to reduce ASCVD risk: An evidence-based review. Evidence-Based Practice, 0, Publish Ahead of Print, .	0.0	0
564	Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. American Journal of Cardiovascular Drugs, 2022, 22, 657-675.	2.2	6
567	Analysis of Adverse Reactions of Aspirin in Prophylaxis Medication Based on FAERS Database. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.	1.3	7
568	Association of Dual Decline in Cognition and Gait Speed With Risk of Dementia in Older Adults. JAMA Network Open, 2022, 5, e2214647.	5.9	29
569	Oridonin Delays Aging Through the AKT Signaling Pathway. Frontiers in Pharmacology, 0, 13, .	3.5	9
571	Proximal femur fractures in patients taking anti-coagulants: has anything changed?. EFORT Open Reviews, 2022, 7, 356-364.	4.1	3

#	ARTICLE	IF	CITATIONS
573	Meta-Analysis of Aspirin for Primary Prevention of Stroke. <i>Yangtze Medicine</i> , 2022, 06, 41-55.	0.1	0
574	Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 208-223.	2.0	17
575	Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	1
576	Aspirin for Primary Stroke Prevention; Evidence for a Differential Effect in Men and Women. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	6
577	A survey of internistsâ€™™ recommendations for aspirin in older adults and barriers to evidence-based use. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 639-646.	2.1	1
578	Extra-Cranial Carotid Artery Stenosis: An Objective Analysis of the Available Evidence. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	13
579	Acetylsalicylic acid in primary prevention of cardiovascular disease. <i>Vnitřni Lekarstvi</i> , 2022, 68, 240-245.	0.2	0
580	Prevention of Coronary Artery Disease in Women. <i>Current Cardiology Reports</i> , 0, , .	2.9	1
581	Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaqueâ€™” Provided by the Society for the Prevention of Symptomatic Heart Disease. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 320-341.	0.2	6
582	SEA 2022 standards for the comprehensive control of cardiovascular risk. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition)</i> , 2022, 34, 130-179.	0.2	1
583	Impact of pharmacist intervention to deprescribe inappropriate aspirin therapy in an outpatient anticoagulation clinic at a community hospital. <i>American Heart Journal Plus</i> , 2022, 17, 100165.	0.6	0
584	Incident Cancer Risk and Signatures Among Older <i>MUTYH</i> Carriers: Analysis of Population-Based and Genomic Cohorts. <i>Cancer Prevention Research</i> , 2022, 15, 509-519.	1.5	1
585	Resumption of Antiplatelet Therapy after Major Bleeding. <i>Thrombosis and Haemostasis</i> , 2023, 123, 135-149.	3.4	4
586	Predictors of Progression in Intraplaque Hemorrhage Volume in Patients With Carotid Atherosclerosis: A Serial Magnetic Resonance Imaging Study. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	0
587	Pharmacological Approaches to Decelerate Aging: A Promising Path. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-25.	4.0	5
588	Aspirin for Primary Prevention of Cardiovascular Diseases: â€™WALTZâ€™ with the Evidence. <i>Current Cardiology Reports</i> , 2022, 24, 1139-1147.	2.9	2
589	Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. <i>New England Journal of Medicine</i> , 2022, 387, 1385-1394.	27.0	51
590	Managing thrombotic risk in patients with diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	8

#	ARTICLE	IF	CITATIONS
591	Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. Mayo Clinic Proceedings, 2022, 97, 1483-1492.	3.0	7
592	A review of pathobiological mechanisms and potential application of medicinal plants for vascular aging: focus on endothelial cell senescence. Medical Journal of Indonesia, 0, , .	0.5	0
593	Prescribed opioid use is associated with adverse cardiovascular outcomes in community-dwelling older persons. ESC Heart Failure, 2022, 9, 3973-3984.	3.1	4
594	Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 1207-1216.	2.4	10
595	Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. Journal of the American College of Cardiology, 2022, 80, 1287-1298.	2.8	45
596	Triggering of ST-elevation myocardial infarction by ultrafine particles in New York: Changes following Tier 3 vehicle introduction. Environmental Research, 2023, 216, 114445.	7.5	4
597	Retrospective Study of Appropriate Primary Prevention in Postmenopausal Women Presenting with a Major Adverse Cardiovascular Endpoint (MACE). Pharmacy (Basel, Switzerland), 2022, 10, 105.	1.6	0
598	Modulation of Glycoprotein VI and Its Downstream Signaling Pathways as an Antiplatelet Target. International Journal of Molecular Sciences, 2022, 23, 9882.	4.1	4
599	The landscape of aging. Science China Life Sciences, 2022, 65, 2354-2454.	4.9	110
600	Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake. Cancer Prevention Research, 2022, 15, 837-846.	1.5	1
601	Prescribing aspirin to older people " where is the line between cardiovascular benefit and upper gastrointestinal bleeding risk?. Internal Medicine Journal, 2022, 52, 1468-1470.	0.8	0
602	Outcomes Associated with 50 mg/d and 100 mg/d Aspirin for the Prevention and Management of Cardiovascular Disease in Chinese Elderly: Single-Center Interim Analysis of a Multicenter, Prospective, Observational Study. International Journal of General Medicine, 0, Volume 15, 7089-7100.	1.8	3
603	Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 0, 13, .	3.5	2
604	Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study. Kidney Medicine, 2022, 4, 100547.	2.0	2
605	Examining evidence of time-dependent treatment effects: an illustration using regression methods. Trials, 2022, 23, .	1.6	2
606	Effects of tiotropium on the risk of coronary heart disease in patients with COPD: a nationwide cohort study. Scientific Reports, 2022, 12, .	3.3	4
607	Educational level differences in the primary and secondary prevention of stroke. Preventive Medicine, 2022, 164, 107283.	3.4	0
608	Scale bar of aging trajectories for screening personal rejuvenation treatments. Computational and Structural Biotechnology Journal, 2022, 20, 5750-5760.	4.1	0

#	ARTICLE	IF	CITATIONS
610	Project rebuild the evidence base (REB): A method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients. <i>Therapie</i> , 2023, 78, 353-365.	1.0	2
611	Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
613	Contemporary use of coronary artery calcium for the allocation of aspirin in light of the 2022 USPSTF guideline recommendations. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100427.	3.0	3
614	XGBoost, A Novel Explainable AI Technique, in the Prediction of Myocardial Infarction: A UK Biobank Cohort Study. <i>Clinical Medicine Insights: Cardiology</i> , 2022, 16, 117954682211336.	1.8	14
615	PRZEGLĄD AKTUALNYCH WYTYCZNYCH I BADAŃ ZASTOSOWANIA KWASU ACETYLOSALICYLOWEGO W PREWENCJI PIERWOTNEJ INCYDENTÓW SERCOWO-NACZYNIOWYCH. , 2019, 17, 20-23.		0
616	Low-dose aspirin as primary prevention for adults without cardiovascular disease. <i>Journal of the American Association of Nurse Practitioners</i> , 0, Publish Ahead of Print, .	0.9	0
617	Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100432.	3.0	10
618	Daily Low-Dose Aspirin and Risk of Serious Falls and Fractures in Healthy Older People. <i>JAMA Internal Medicine</i> , 2022, 182, 1289.	5.1	5
619	Risks and benefits of continuation and discontinuation of aspirin in elective craniotomies: a systematic review and pooled-analysis. <i>Acta Neurochirurgica</i> , 2023, 165, 39-47.	1.7	5
620	Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE). <i>Cureus</i> , 2022, , .	0.5	0
622	Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 94-102.	3.7	5
623	Effect of fruitflow on platelet function: A randomized placebo-controlled clinical trial in middle-aged and elderly subjects. <i>Journal of Functional Foods</i> , 2022, 99, 105315.	3.4	0
624	Medication considerations including safety and its principles in geriatric dentistry. <i>Journal of Advanced Pharmacy Education and Research</i> , 2022, 12, 67-76.	1.1	0
626	Rationale and Design of LAPIS: A Multicenter Prospective Cohort Study to Investigate the Efficacy and Safety of Low-Dose Aspirin in Elderly Chinese Patients. <i>International Journal of General Medicine</i> , 0, Volume 15, 8333-8341.	1.8	0
627	Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2023, 261, 1413-1421.	1.9	3
628	Invasive vs. Conservative Treatment Approach among Elderly Patients Admitted with Acute ST-Segment Elevation Myocardial Infarction. <i>Annals of Geriatric Medicine and Research</i> , 0, , .	1.8	0
629	Doxorubicin-Induced Platelet Activation and Clearance Relieved by Salvianolic Acid Compound: Novel Mechanism and Potential Therapy for Chemotherapy-Associated Thrombosis and Thrombocytopenia. <i>Pharmaceuticals</i> , 2022, 15, 1444.	3.8	2
630	Aspirin for primary prevention of cardiovascular disease in women. <i>Menopause</i> , 2022, Publish Ahead of Print, .	2.0	0

#	ARTICLE	IF	CITATIONS
631	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2023. <i>Diabetes Care</i> , 2023, 46, S158-S190.	8.6	156
632	GFR Variability, Survival, and Cardiovascular Events in Older Adults. <i>Kidney Medicine</i> , 2023, 5, 100583.	2.0	2
633	Effect of aspirin in patients with established asymptomatic carotid atherosclerosis: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
634	Acetylsalicylic Acid – Primus Inter Pares in Pharmacology. <i>Molecules</i> , 2022, 27, 8412.	3.8	6
635	Ageing and aging-related diseases: from molecular mechanisms to interventions and treatments. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	150
636	Acute, periprocedural and longterm antithrombotic therapy in older adults. <i>European Heart Journal</i> , 2023, 44, 262-279.	2.2	18
637	The Aging Heart: A Molecular and Clinical Challenge. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16033.	4.1	12
638	Caloric restriction induced epigenetic effects on aging. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	2
639	Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2023, 43, 6-11.	1.4	7
640	The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 521-532.	4.4	7
641	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1. <i>Contemporary Cardiology</i> , 2023, , 1-65.	0.1	0
642	Adherence to European guidelines for the use of acetylsalicylic acid in primary health care. <i>Revista Portuguesa De Cardiologia</i> , 2023, , .	0.5	1
643	Antithrombotic Management in Spine Surgery in the Elderly. , 2023, , 19-49.		0
644	Hallmarks of aging: An expanding universe. <i>Cell</i> , 2023, 186, 243-278.	28.9	894
645	Evaluation of a Pharmacist-Driven Ambulatory Aspirin Deprescribing Protocol. , 2022, 39, .		0
646	Acetylsalicylic acid in the primary prevention of vascular complications in patients without clinically apparent atherosclerosis: how to balance risk and benefit?. <i>Atherothrombosis</i> , 2023, 12, 8-20.	0.3	0
647	Association Between CKD and Major Hemorrhage in Older Persons: Data From the Aspirin in Reducing Events in the Elderly Randomized Trial. <i>Kidney International Reports</i> , 2023, 8, 737-745.	0.8	3
648	Network pharmacology and experimental study of phenolic acids in salvia miltiorrhiza bung in preventing ischemic stroke. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	3

#	ARTICLE	IF	CITATIONS
650	Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS). <i>Cancers</i> , 2023, 15, 1017.	3.7	1
652	Aspirin With or Without Statin in Individuals Without Atherosclerotic Cardiovascular Disease Across Risk Categories. , 2023, 2, 100197.		4
653	What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?. <i>Cardiometabolic Syndrome Journal</i> , 2023, 3, 41.	0.6	1
654	Socioeconomic, Behavioural, and Social Health Correlates of Optimism and Pessimism in Older Men and Women: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3259.	2.6	0
655	Low- or high-dose preventive aspirin use and risk of death from all-cause, cardiovascular disease, and cancer: A nationally representative cohort study. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	3
656	Targeting cerebral small vessel disease to promote healthy aging: Preserving physical and cognitive functions in the elderly. <i>Archives of Gerontology and Geriatrics</i> , 2023, 110, 104982.	3.0	3
657	Cognitive trajectories and incident dementia after a cardiovascular event in older adults. <i>Alzheimer's and Dementia</i> , 2023, 19, 3670-3678.	0.8	2
658	Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	2.9	2
659	Evaluation of the Appropriateness of Aspirin Therapy in a Veteran Population. , 2023, 40, .		0
660	Associations of body size with all-cause and cause-specific mortality in healthy older adults. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
661	The association between frailty and incident cardiovascular disease events in community-dwelling healthy older adults. <i>American Heart Journal Plus</i> , 2023, 28, 100289.	0.6	0
662	The polypill from a public-health perspective. <i>Lancet Neurology</i> , The, 2023, 22, 294-295.	10.2	2
663	IDF2022-1146 Longitudinal relationship between glycemic status and disability-free survival in a community-dwelling older cohort. <i>Diabetes Research and Clinical Practice</i> , 2023, 197, 110468.	2.8	0
664	Low-dose aspirin in the primary prevention of cardiovascular diseases: A retrospective, propensity score matched study. <i>Atherosclerosis</i> , 2023, 371, 54-60.	0.8	0
665	Subdural hygroma and hemorrhagic conversion after microsurgical clipping for unruptured intracranial aneurysm. <i>Acta Neurochirurgica</i> , 2023, 165, 1251-1260.	1.7	1
666	Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1172-1181.	1.8	3
667	Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease—A Translational Perspective. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6280.	4.1	1
668	Association of polygenic scores with chronic kidney disease phenotypes in a longitudinal study of older adults. <i>Kidney International</i> , 2023, 103, 1156-1166.	5.2	3

#	ARTICLE	IF	CITATIONS
669	Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). <i>BMJ Open</i> , 2023, 13, e069915.	1.9	9
670	Current concepts and novel targets for antiplatelet therapy. <i>Nature Reviews Cardiology</i> , 2023, 20, 583-599.	13.7	7
671	Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2023, 147, 1471-1487.	1.6	20
672	Self-Reported Early and Later Life Weight and the Risk of All-Cause Mortality in Older Adults. <i>Journal of Nutrition, Health and Aging</i> , 2023, 27, 301-308.	3.3	1
673	Potential Novel RNA-Targeting Agents for Effective Lipoprotein(a) Lowering: A Systematic Assessment of the Evidence from Completed and Ongoing Developmental Clinical Trials. <i>Journal of Cardiovascular Pharmacology</i> , 2023, Publish Ahead of Print, .	1.9	2
674	Low-dose aspirin therapy for primary prevention of cardiovascular disease: where are we at?. <i>European Journal of Preventive Cardiology</i> , 0, , .	1.8	0
675	Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 311-328.	1.5	2
676	Influence of aspirin on aging skeletal muscle: Insights from a cross-sectional cohort of septuagenarians. <i>Physiological Reports</i> , 2023, 11, .	1.7	1
677	Hallmarks of cardiovascular ageing. <i>Nature Reviews Cardiology</i> , 2023, 20, 754-777.	13.7	28
678	Prediabetes, diabetes and loss of disability-free survival in a community-based older cohort: a post-hoc analysis of the ASPirin in Reducing Events in the Elderly trial. <i>Age and Ageing</i> , 2023, 52, .	1.6	0
679	Redefining the Roles of Aspirin Across the Spectrum of Cardiovascular Disease Prevention. <i>Current Cardiology Reviews</i> , 2023, 19, .	1.5	0
681	Validation of newly derived polygenic risk scores for dementia in a prospective study of older individuals. <i>Alzheimer's and Dementia</i> , 2023, 19, 5333-5342.	0.8	1
682	Low-Dose Aspirin after ASPRE—More Questions Than Answers? Current International Approach after PE Screening in the First Trimester. <i>Biomedicines</i> , 2023, 11, 1495.	3.2	1
683	Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials. <i>Clinical Trials</i> , 0, , 174077452311770.	1.6	0
684	Medication changes implemented during medication reviews and factors related to deprescribing: Posthoc analyses of a randomized clinical trial in geriatric outpatients with polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 3291-3301.	2.4	1
685	Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis. <i>Current Cardiology Reports</i> , 2023, 25, 693-710.	2.9	3
686	Position statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and/or anticoagulant therapy. <i>Indian Journal of Gastroenterology</i> , 0, , .	1.4	1
687	Prevention of aspirin-mediated secondary toxicity by combined treatment of carotenoids in macrophages. <i>3 Biotech</i> , 2023, 13, .	2.2	0

#	ARTICLE	IF	CITATIONS
688	Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly. <i>Annals of Internal Medicine</i> , 2023, 176, 913-921.	3.9	7
689	Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study. <i>Medicine (United States)</i> , 2023, 102, e34109.	1.0	0
690	Hybrids of carbonic anhydrase and cyclooxygenase inhibitors attenuate cardiac hypoxic inflammatory injuries. <i>European Journal of Pharmacology</i> , 2023, 950, 175751.	3.5	0
692	The association of allopurinol with persistent physical disability and frailty in a large community based older cohort. <i>Journal of the American Geriatrics Society</i> , 0, , .	2.6	1
693	Aspirin does not reduce fracture and fall risk in healthy older people. <i>Drug and Therapeutics Bulletin</i> , 2023, 61, 85-85.	0.3	0
694	Potentially inappropriate medications and potential prescribing omissions in hospitalised older adults in New Zealand: A retrospective study. <i>Australasian Journal on Ageing</i> , 2023, 42, 668-674.	0.9	2
695	Health Characteristics and Aspirin Use in Participants at the Baseline of the ASPirin in Reducing Events in the Elderly " eXTension (ASPREE-XT) Observational Study. <i>Contemporary Clinical Trials</i> , 2023, 130, 107231.	1.8	5
696	Antiplatelet Therapy or Not for Asymptomatic/Incidental Lacunar Infarction. <i>Stroke</i> , 2023, 54, 1954-1959.	2.0	0
697	Low-Dose Aspirin during Pregnancy and Postpartum Bleeding. <i>American Journal of Perinatology</i> , 0, , .	1.4	0
698	Clopidogrel vs Aspirin in the Chronic Maintenance Period for Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2023, 16, 1553-1555.	2.9	0
699	A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11132.	4.1	1
700	Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in <sc>nonâ€œirrhotic</sc> patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 0, , .	3.7	3
701	Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People. <i>JAMA Network Open</i> , 2023, 6, e2325803.	5.9	7
702	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With ChronicÂCoronary Disease. <i>Journal of the American College of Cardiology</i> , 2023, 82, 833-955.	2.8	48
703	Aspirin 15cH has Different Effects on Morphology and Function of Lipopolysaccharide-Challenged RAW 264.7 Macrophages In Vitro Compared to a Pharmacological Dose of Aspirin. <i>Homeopathy</i> , 0, , .	1.0	0
705	Compliance-Adjusted Estimates of Aspirin Effects Among Older Persons in the ASPREE Randomized Trial. <i>American Journal of Epidemiology</i> , 2023, 192, 2063-2074.	3.4	1
706	Long-term Survival Rate Following Myocardial Infarction and the Effect of Discharge Medications on the Survival Rate. <i>Journal of Research in Health Sciences</i> , 2022, 22, e00567.	1.0	0
707	Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 5284.	2.4	0

#	ARTICLE	IF	CITATIONS
708	Hyperoside: A Review of Resources, Synthesis Pathways, Physicochemical Properties, Metabolism, Pharmacological Activities, Clinical Trials and Human Studies, Toxicology and Safety, Marketed Products, and Patents. , 2023, , 1-103.		0
709	Aspirin for the Primary Prevention of Vascular Ischemic Events: An Updated Systematic Review and Meta-analysis to Support Shared Decision-Making. CJC Open, 2023, 5, 881-890.	1.5	1
710	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2023, 148, .	1.6	84
711	Multilayered safety framework for living diagnostics in the colon. Frontiers in Systems Biology, 0, 3, .	0.7	0
712	Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms. International Journal of Molecular Sciences, 2023, 24, 12700.	4.1	0
713	Aspirin for primary prevention in patients with high cardiovascular risk: insights from CORE-Thailand registry. Scientific Reports, 2023, 13, .	3.3	0
714	Association of low-dose aspirin use for primary prevention with self-reported kidney stones prevalence: a cross-sectional study. World Journal of Urology, 0, , .	2.2	0
715	Aspirin and lipoprotein(a) in primary prevention. Current Opinion in Lipidology, 2023, 34, 214-220.	2.7	0
718	Low-dose Aspirin Does Not Prevent Stroke in Healthy People. Neurology Today: an Official Publication of the American Academy of Neurology, 2023, 23, 5,11-11.	0.0	0
719	Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. American Journal of Medicine, 2023, , .	1.5	1
720	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events Comparing East Asians With Westerners. JACC Asia, 2023, 3, 846-862.	1.5	0
722	Aging and Antithrombotic Treatment. Antioxidants and Redox Signaling, 0, , .	5.4	0
723	Aspirin for Primary Prevention. JACC Asia, 2023, 3, 863-864.	1.5	0
724	Management of Anticoagulant and Antiplatelet Agents in Acute Gastrointestinal Bleeding and Prevention of Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America, 2024, 34, 205-216.	1.4	0
725	Perioperative Low-Dose Aspirin Management for Planned Clipping Surgery: When, How Long, and With What Precautions?. Neurosurgery, 2024, 94, 597-605.	1.1	0
726	Actionable autophagy checkpoints in cardiovascular ageing. European Heart Journal, 0, , .	2.2	1
727	Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
728	Implications of direct oral anticoagulation and antiplatelet therapy in intensive care. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2020, 22, 181-188.	0.1	0

#	ARTICLE	IF	CITATIONS
729	Why some Patients Benefit from Participating in a Sham Surgery Trial. <i>Annals of Surgery</i> , 2024, 279, 577-582.	4.2	0
730	Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000207923.	1.1	3
731	ErwÃ¼nschte ASS-Nebenwirkung: Antiinflammatorischer Effekt senkt Diabetesrisiko. , 0, , .		0
733	Aspirin intervention before ICU admission reduced the mortality in critically ill patients with acute kidney injury: results from the MIMIC-IV. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
734	Aspirin use is safe in patients undergoing transbronchial lung cryobiopsy. <i>Heliyon</i> , 2023, 9, e22047.	3.2	0
735	Do We Still Need Aspirin in Coronary Artery Disease?. <i>Journal of Clinical Medicine</i> , 2023, 12, 7534.	2.4	0
736	Genome-Wide Association Study of Cardiovascular Resilience Identifies Protective Variation in the <i>CETP</i> Gene. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	0
737	Chronic Kidney Disease in the Elderly. , 2023, , 477-483.		0
738	Should I take aspirin? A qualitative study on the implementation of a decision aid on taking aspirin for bowel cancer prevention. <i>Family Medicine and Community Health</i> , 2023, 11, e002423.	1.6	0
739	10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes</i> 2024. <i>Diabetes Care</i> , 2024, 47, S179-S218.	8.6	8
740	Causal relationship between aspirin consumption and heart failure: a Mendelian randomization study. <i>ESC Heart Failure</i> , 0, , .	3.1	0
742	Acceptability of aspirin for cancer preventive therapy: a survey and qualitative study exploring the views of the UK general population. <i>BMJ Open</i> , 2023, 13, e078703.	1.9	0
743	Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2024, 12, 98-106.	11.4	1
744	Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis. <i>Journal of the American Heart Association</i> , 2024, 13, .	3.7	1
745	Anti-Aging Drugs and the Related Signal Pathways. <i>Biomedicines</i> , 2024, 12, 127.	3.2	0
746	Inflammation as a New Therapeutic Target among Older Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2024, 13, 363.	2.4	0
747	PrÃ©vention cardiovasculaire. , 2023, , 831-837.		0
748	Aspirin for Primary Prevention of Cardiovascular Disease: What We Now Know. <i>Journal of Cardiology and Cardiovascular Medicine</i> , 2024, 9, 006-013.	0.2	0

#	ARTICLE	IF	CITATIONS
749	Preventive cardiology for the aging population: how can we better design clinical trials of statins?. Expert Review of Cardiovascular Therapy, 2024, 22, 13-18.	1.5	0
751	Discontinuation of antiplatelet therapy after stent-assisted coil embolisation of cerebral aneurysm: a nationwide cohort study. Stroke and Vascular Neurology, 0, , svn-2023-002882.	3.3	0
752	Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment. Current Atherosclerosis Reports, 2024, 26, 111-118.	4.8	1
753	Beispiele der klassischen Arzneimittelforschung. , 2023, , 27-43.		0
754	Coronary events in elderly patients with non-valvular atrial fibrillation: a prespecified sub-analysis of the ANAFIE registry. Cardiovascular Intervention and Therapeutics, 2024, 39, 145-155.	2.3	0
755	Prevention of preeclampsia. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2024, 93, 102481.	2.8	0
757	GÃ¼ncel KÃ±lavuzlara GÃ¶re Aspirinin Birincil Korunmadaki RolÃ¼: Aile Hekimleri iÃin Ã–neriler. Turkish Journal of Family Medicine & Primary Care, 2024, 18, 120-125.	0.6	0
759	Effect of Low-Dose Aspirin on the Elderly. Cureus, 2024, , .	0.5	0
760	Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis. Circulation, 2024, 149, 722-724.	1.6	0
761	The ASPREE Healthy Ageing Biobank: Methodology and participant characteristics. PLoS ONE, 2024, 19, e0294743.	2.5	0
762	Clinical evaluation of side effects resulting from the use of aspirin cardio. AIP Conference Proceedings, 2024, , .	0.4	0
763	Effectiveness of Aspirin on Major COPD Outcomes: A Prevalent New-User Design Observational Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2024, 21, .	1.6	0
765	Drugs associated with increased bleeding risk. , 2024, , 175-200.		0
766	Modifying platelets at their birth: anti-thrombotic therapy without haemorrhage. Frontiers in Pharmacology, 0, 15, .	3.5	0
767	Coronary atherosclerosis in athletes: recent insights and clinical considerations. British Journal of Sports Medicine, 0, , bjsports-2023-107938.	6.7	0
770	KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 2024, 105, S117-S314.	5.2	0